R&D Trends 2012

NEW YORK, June 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

R&D Trends 2012
http://www.reportlinker.com/p0885032/RD-Trends-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Research_and_Development

Mounting pressure to reduce the cost of R&D and boost productivity has resulted in pharma companies undertaking radical strategies as the search for efficiency continues. With the ongoing patent cliff triggering a wave of patent expiries, pharmaceutical R&D is at a turning point. Provides an overview of the key R&D challenges facing pharma today as well as pharma's solutions to alleviate these pressures. Trend analysis of R&D metrics, both industry wide and on a case-by-case basis for key Big Pharma companies. Insight into pharma's R&D externalization strategies, supported by case study analysis. Case study analysis comparing and contrasting the performance and clinical pipelines AstraZeneca, Pfizer, Roche, and Sanofi. As a short-term solution to increase profitability, the numerous companies have slashed their budgets, including R&D investment, but in the long term, downsizing may not prove to be sustainable, and as a result companies are placing a greater focus on collaborative R&D. Externalization has become a core strategy in order to overcome R&D challenges, with companies opting to source their drug candidates via M&A, collaborations, licensing/co-development deals, venture capital investments, and partnerships with universities, spreading the cost and risk of drug development. Pharma companies have re-evaluated their R&D pipelines in recent years, focusing on high growth, niche areas, while deprioritizing areas with low unmet meet. Consequently, leading pharma companies are focusing on developing candidates for secondary care indications while simultaneously reducing their efforts in primary care diseases. What are the key R&D challenges facing pharma today? What strategies is the industry employing to alleviate pressures on R&D? What types of externalization strategies are pharma companies using to bolster the clinical pipelines? What are the key drivers and strategies that have shaped the clinical pipelines of leading pharma players?

EXECUTIVE SUMMARY--Introduction
--Strategic scoping and focus
-- Key findings - R&D Productivity
- Pharma's Response
- Strategies driving pharmaceutical sales growth out to 2016

--Related reports

R&D PRODUCTIVITY--Improving return on investment remains a key challenge in terms of R&D
--Increasing cost of R&D - Larger, longer, and more complex clinical trials drive up cost
- Clinical trial success rates could improve by using adaptive trials

--Decreasing R&D budgets - Big Pharma companies refocus their R&D pipeline in response to budget cuts

--Issues with clinical trial recruitment
--Collecting economic data in order to secure reimbursement approval is essential
--Regulatory changes have a largely negative impact on pharma R&D - Greater focus on pharmacovigilance
- US approval times could increase
- US post-marketing studies may soon need to be conducted under direct supervision
- Collaboration between the FDA and EMA is intensifying

--Replacing sales from expiring blockbuster drugs will be a challenge - The number of drug approvals increased in 2011

PHARMA'S RESPONSE--Pharma uses externalization to drive growth
--Pharma employs a range of external partnerships to boost R&D productivity
--Partnerships with universities - Pfizer adopts the ultimate "open innovation" approach to cherry pick early-stage compounds

--Venture capital investment - Sanofi targets early-stage research to stay ahead of the curve

--Licensing - Licensing deals are increasingly focusing on milestone payments to minimize financial risks

--Collaborations - Competitors become collaborators leading to the emergence of a novel combination therapies

--M&A - Premiums rise in line with competition for acquisition targets
- The line between licensing and M&A deals is blurring

--Re-organization - Re-organization of business operations is spurred by challenging times
- Bristol-Myers Squibb is divesting its ex-pharma units to increase operating margins and generate cash for a small acquisition

--Outsourcing - Big Pharma enter preferred provider deals to improve outsourcing efficiencies

--Spin-outs - GlaxoSmithKline readily turns to spin-outs in order to continue development of deprioritized projects
- Abbott spins-out its pharmaceutical business to create new business opportunities

CASE STUDY ANALYSIS OF CLINICAL R&D PIPELINES: 2007 VS. 2011--Strategies driving pharmaceutical sales growth out to 2016
--Big Pharma R&D strategies in response to sales forecasts - AstraZeneca, Pfizer, Sanofi, and Roche sales forecasts
- Roche, Sanofi, Pfizer, and AstraZeneca R&D strategies to drive future growth
- Indications with low unmet need are deprioritized
- Externalization has become the mainstay of R&D

--Roche has successfully overhauled its R&D strategy through numerous deals - Roche has successfully locked in one of the most lucrative pipelines ahead of competition
- Roche is re-entering the primary care markets through externally sourced drugs
- Roche pursues an aggressive strategy to bolster its specialty care segment

--Sanofi's diversification strategy is facilitated by its deal-making activity - Sanofi's vaccines division is crucial to its diversification strategy
- The acquisition of Genzyme has positioned Sanofi at the forefront of the orphan drug sector
- Sanofi's partnership with Regeneron is proving fruitful in terms of its oncology pipeline

--Pfizer's new launch revenues will be insufficient to drive future sales growth - Pfizer's acquisition of Wyeth boost its presence in the biologics and vaccines arena
- Pfizer expands its small molecule portfolio through acquiring King Pharmaceuticals

--AstraZeneca's clinical pipeline continues to suffer from late-stage woes - Cardiovascular research was deprioritized following several late-stage setbacks
- Oncology has become AstraZeneca's primary R&D focus
- Externally sourced drugs are key to AstraZeneca's strategy despite disappointing performances to date

BIBLIOGRAPHY--Publications and online articles
--Datamonitor reports and products

APPENDIX--Exchange rates used in this report

TABLES--Table: Staff lay-offs by leading pharma companies, 2011
--Table: US new molecular entity and Biologic License Application approvals, 2011
--Table: Notable industry-academia partnerships announced during 2011–12
--Table: Pharma's corporate venture capital businesses
--Table: Notable corporate venture capital deals completed, 2011–12
--Table: Currency exchange rates, 2011

FIGURES--Figure: The relationship between pharma's strategic responses to boost R&D productivity
--Figure: Drivers and resistors for global sales growth of prescription products for the leading pharma companies, as well as their strategic responses, 2011–16
--Figure: Global R&D spend and new drug approvals, 1990–2010
--Figure: The growing cost of drug discovery and allocation of R&D investment, by function (%), 2010 vs. 2011
--Figure: The principal goal of adaptive design: faster and shorter clinical trials
--Figure: Advantages and disadvantages of adaptive clinical trials
--Figure: R&D productivity for the top 10 R&D budgets, 2011
--Figure: Classification of economic evaluations according to the method of data collection
--Figure: Pharma has had to grapple with growing regulatory pressures
--Figure: New molecular entities and Biologic License Applications approved by the FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, 2005–11
--Figure: Combined global prescription sales for the top 40 branded pharma companies, by product source ($bn), 2003–16
--Figure: Sales growth for leading branded pharma companies, by product source, 2011–16
--Figure: The relationship between pharma's strategic responses to boost R&D productivity
--Figure: Venture capital investment in the US biotechnology sector, 1995–2011
--Figure: Key drivers and resistors facing licensees and licensors in the pharmaceutical industry
--Figure: Two types of M&A models reflect different company growth strategies
--Figure: Abbott's new corporate structure – separation into two companies
--Figure: Drivers and resistors for global sales growth of prescription products for the leading pharma companies, as well as their strategic responses, 2011–16
--Figure: Forecast sales growth ($bn), 2012–16
--Figure: Number of drug candidates in clinical development (Phase I, II, and III) for AstraZeneca, Pfizer, Sanofi, and Roche, 2007 vs. 2011
--Figure: Number of drug candidates in clinical development (Phase I, II and III) according to indication for AstraZeneca, Roche, Sanofi and Pfizer only, 2007 vs. 2011
--Figure: Sales growth (by primary indication only) for the leading pharma companies, 2010–16
--Figure: Proportion of drug candidates in clinical development that are externally sourced (%), 2007 vs. 2011
--Figure: Roche's R&D pipeline (Phase I, II and III), 2007 vs. 2011
--Figure: Sanofi's R&D pipeline (Phase I, II, and III), 2007 vs. 2011
--Figure: Pfizer's R&D pipeline (Phase I, II, and III), 2007 vs. 2011
--Figure: AstraZeneca's R&D pipeline (Phase I, II, and III), 2007 vs. 2011

Companies mentioned

Abbott Laboratories, Banco Santander, S.A., Caterpillar Logistics Services, Inc., Dairy Farm International Holdings Limited, Deutsche Telekom AG, Devoteam SA, F. Hoffmann-La Roche Ltd, GE Healthcare, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Merck KGaA, Pfizer Inc., Schindler Holding Ltd., Seattle Genetics, Inc., Telstra Corporation Limited

To order this report:
: R&D Trends 2012

Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker